Search Results - "Katzen, Harvey"

Hemoglobin SC smear recorded with a smartphone by Trikalinos, Nikolaos A., Katzen, Harvey I.

“…Key Clinical Message Taking photographs of microscope slides generally requires expensive equipment and a lot of effort. We demonstrate a technique to take…”
Get full text

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia by Flowers, Christopher R, Brown, Jennifer R, Rosenthal, Hilary, Stock, Wendy, Katzen, Harvey I, Cohen, Jonathon B, Sinha, Rajni, Lakhanpal, Shailendra, Leis, Jose F, Waller, Edmund K, Jaye, David L

“…Micro-Abstract We evaluated alemtuzumab in combination with fludarabine for patients with relapsed chronic lymphocytic leukemia. Sixty patients were enrolled…”
Get full text

HRR testing and PARPi utilization among patients with metastatic castration resistant prostate cancer treated in the real-world setting by Vasudevan, Anupama, Katzen, Harvey I., Gart, Mike, Blanc, Simon

“…91 Background: HRR mutations (HRRm) have prognostic value in metastatic castration-resistant prostate cancer (mCRPC). Treatment with poly (ADP-ribose)…”
Get full text

HSR24-156: Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States by Yu, Jingbo, Vasudevan, Anupama, Katzen, Harvey, Braunstein, Evan

Get more information

Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera (PV) Managed at Community Practices in the United States (US) by Yu, Jingbo, Vasudevan, Anupama, Katzen, Harvey, Braunstein, Evan

Get full text

MPN-109 Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera (PV) Managed at Community Practices in the United States (US) by Yu, Jingbo, Vasudevan, Anupama, Katzen, Harvey, Braunstein, Evan

“…PV is a myeloproliferative neoplasm that presents with increased blood counts. NCCN guidelines recommend phlebotomy to maintain hematocrit <45% and…”
Get full text

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL) by Hou, Jing-Zhou, Gart, Michael, Vasudevan, Anupama, Katzen, Harvey I., Choksi, Rushir, Blanc, Simon

“…Background: CLL tx options have recently expanded to include second generation (gen) Bruton tyrosine kinase inhibitors (BTKi) and b-cell 2 inhibitors (BCL2i)…”
Get full text

Patterns in maintenance therapy use in advanced ovarian cancer patients: Real-world data analysis by Taylor, Sarah, Gart, Michael, Choksi, Rushir, Thomas, Roby, Katzen, Harvey, Donegan, Janet, Vasudevan, Anupama, Alwon, Erin, Varughese, Prateesh, Blanc, Simon

Get full text

BRCA and homologous recombination repair deficiency testing in advanced ovarian cancer: A real-world data analysis by Taylor, Sarah, Gart, Michael, Thomas, Roby, Choksi, Rushir, Katzen, Harvey, Donegan, Janet, Vasudevan, Anupama, Alwon, Erin, Varughese, Prateesh, Blanc, Simon

Get full text

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice by Rossetti, James M., Choksi, Rushir, Suthar, Purvi, Davis, Phoebe, Vasudevan, Anupama, Dave, Poras, Vaidya, Varun, Wang, Brandon, Katzen, Harvey I.

“…Background: Myelofibrosis (MF) is a myeloid neoplasm characterized by splenomegaly, constitutional symptoms, and cytopenias. Notably, worsening cytopenias in…”
Get full text

HSR24-142: Real-World Clinical Benefit Among Patients (pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept by Patel, Kashyap, Snyder, Brandy, Tang, Derek, Chatterjee, Debanjana, Vasudevan, Anupama, Mordi, Uchechukwu, Katzen, Harvey, Li, John, Aton, Lindsay, McBride, Ali

Get more information

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study by Scott, Jeffrey A., Katzen, Harvey I., Lennerz, Jochen K, Johnson, Melissa Lynne, Gordan, Lucio N., Dumanois, Robert H, Quagliata, Luca, Ritterhouse, Lauren, Cappuzzo, Federico, Vasudevan, Anupama, Sura, Teena, English, Sandy, Wang, Brandon, Varughese, Prateesh, Choksi, Rushir J.

“…9030 Background: Guidelines (NCCN, CAP/IASLC/AMP) recommend clinical molecular testing of patients with advanced NSCLC to inform therapy decisions. We…”
Get full text

POSTER: MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX) by Jain, Tania, Katzen, Harvey, Zeng, Jia, Nguyen, Hiep, Aton, Lindsay, Qureshi, Parisa, Fares, Marielle, Shih, Yu-Hsuan, Tang, Derek, Vergara, Sara, DeGutis, Irene S., Gerds, Aaron T.

Get full text

MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX) by Jain, Tania, Katzen, Harvey, Zeng, Jia, Nguyen, Hiep, Aton, Lindsay, Qureshi, Parisa, Fares, Marielle, Shih, Yu-Hsuan, Tang, Derek, Vergara, Sara, DeGutis, Irene S., Gerds, Aaron T.

“…Fedratinib (FEDR) and pacritinib (PAC) were approved by the FDA in August 2019 and February 2022, respectively, for treatment of intermediate- and high-risk…”
Get full text

Abstract PO2-18-02: Utilization of Granulocyte Colony-Stimulating Factor (GCSF) in the Management of Patients (pts) on Sacituzumab Govitecan-hziy (SG) and Impact on Duration of Therapy (DOT) by Gorantla, Vikram, Alwon, Erin, Gart, Mike, Li, John, Blanc, Simon, Brenneman, Dawn, Genser, Emma, Varughese, Prateesh, Scott, Justin, Katzen, Harvey

“…Background: An examination was conducted to understand the prevalence of neutropenia in pts managed with SG in the real-world setting, as the ASCENT trial…”
Get full text

Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT) by Gorantla, Vikram, Alwon, Erin, Gart, Mike, Li, John, Blanc, Simon, Brenneman, Dawn, Varughese, Prateesh, Scott, Justin, Katzen, Harvey

“…Background: As the Phase 3 ASCENT trial’s safety analysis found that a 10m/kg dose of SG resulted in better efficacy than treatment with a lower dose, this…”
Get full text

Abstract PO2-18-03: Comparison of Provider Adoption of Antibody-Drug Conjugates Among Breast Cancer Patients (pts) and Impact on Duration of Therapy (DOT) by Choksi, Rushir, Gorantla, Vikram, Gart, Mike, Blanc, Simon, Alwon, Erin, Brenneman, Dawn, Varughese, Prateesh, Scott, Justin, Katzen, Harvey

“…Background: An assessment was performed to understand the degree of post-approval provider adoption of two antibody-drug conjugates, fam-trastuzumab…”
Get full text

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs by Kluetz, Paul G, Keegan, Patricia, Demetri, George D, Thornton, Katherine, Sul, Joohee, Kim, Janice, Katzen, Harvey, Burke, Laurie Beth, Harvey, R Donald, Alebachew, Elleni, Agrawal, Sundeep, Nair, Abhilasha, Donoghue, Martha, Pierce, William F, Shord, Stacy S, Gao, Jennifer J, Pazdur, Richard

“…The FDA conducts independent reviews of scientific data obtained with investigational drug products to ensure that they are safe and effective. As a result of…”
Get full text

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL) by Flowers, Christopher, Rosenthal, Hilary, Brown, Jennifer, Stock, Wendy, Katzen, Harvey, Lakhanpal, Shailendra, Jaye, David

“…Introduction: In patients (pts) with relapsed/refractory CLL, responses achieved with conventional salvage chemotherapy may have limited durability, likely due…”
Get full text

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study by Brown, Jennifer R., Stock, Wendy, Katzen, Harvey I., Suarez, Agustin J., Lakhanpal, Shailendra, Leis, Jose F., Flowers, Christopher

“…Background. Alemtuzumab (CAMPATH) is the most effective single-agent therapy available for the treatment of chronic lymphocytic leukemia (CLL). Previous…”
Get full text